Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma.

Kim HS, Sung JS, Yang SJ, Kwon NJ, Jin L, Kim ST, Park KH, Shin SW, Kim HK, Kang JH, Kim JO, Park JY, Choi JE, Yoon H, Park CK, Yang KS, Seo JS, Kim YH.

PLoS One. 2013 Dec 20;8(12):e81975. doi: 10.1371/journal.pone.0081975. eCollection 2013.

2.

EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Funazo T, Yasuda Y, Hirai T.

Anticancer Res. 2017 May;37(5):2721-2725.

PMID:
28476851
3.

Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.

Yeo CD, Kim JW, Kim KH, Ha JH, Rhee CK, Kim SJ, Kim YK, Park CK, Lee SH, Park MS, Yim HW.

Lung Cancer. 2013 Aug;81(2):207-12. doi: 10.1016/j.lungcan.2013.04.023. Epub 2013 May 29.

PMID:
23726527
4.

Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer.

Yoon SH, Choi YD, Oh IJ, Kim KS, Choi H, Chang J, Shin HJ, Park CK, Kim YC.

Cancer Res Treat. 2015 Oct;47(4):661-9. doi: 10.4143/crt.2014.282. Epub 2015 Feb 23.

5.

Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY.

Lung Cancer. 2012 Mar;75(3):321-5. doi: 10.1016/j.lungcan.2011.08.005. Epub 2011 Sep 17.

PMID:
21930325
6.

Reliable detection of rare mutations in EGFR gene codon L858 by PNA-LNA PCR clamp in non-small cell lung cancer.

Skronski M, Chorostowska-Wynimko J, Szczepulska E, Szpechcinski A, Rudzinski P, Orlowski T, Langfort R.

Adv Exp Med Biol. 2013;756:321-31. doi: 10.1007/978-94-007-4549-0_39.

PMID:
22836650
7.

Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.

Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.

Lung Cancer. 2014 Aug;85(2):161-7. doi: 10.1016/j.lungcan.2014.04.009. Epub 2014 Apr 29.

PMID:
24857785
8.

A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.

Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, Kawahara M, Abe H, Yamaguchi T, Akiba J, Takamori S, Hayashi A, Kage M.

Lung Cancer. 2012 Oct;78(1):39-44. doi: 10.1016/j.lungcan.2012.07.002. Epub 2012 Jul 31.

PMID:
22858448
9.

Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.

Ikeda T, Nakamura Y, Yamaguchi H, Tomonaga N, Doi S, Nakatomi K, Iida T, Motoshima K, Mizoguchi K, Nagayasu T, Tsukamoto K, Kohno S.

Clin Lung Cancer. 2012 Sep;13(5):369-74. doi: 10.1016/j.cllc.2012.01.008. Epub 2012 Mar 10.

PMID:
22410386
10.

Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients.

Shaozhang Z, Ming Z, Haiyan P, Aiping Z, Qitao Y, Xiangqun S.

Med Oncol. 2014 May;31(5):926. doi: 10.1007/s12032-014-0926-3. Epub 2014 Apr 20.

PMID:
24748405
11.

EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method.

Watanabe K, Fukuhara T, Tsukita Y, Morita M, Suzuki A, Tanaka N, Terasaki H, Nukiwa T, Maemondo M.

Can Respir J. 2016;2016:5297329. doi: 10.1155/2016/5297329. Epub 2016 Jul 13.

12.

Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system.

Suzawa K, Yamamoto H, Ohashi K, Hashida S, Tomida S, Kubo T, Maki Y, Soh J, Tsukuda K, Kiura K, Miyoshi S, Toyooka S.

Oncol Rep. 2017 May;37(5):3100-3106. doi: 10.3892/or.2017.5567. Epub 2017 Apr 11.

PMID:
28405680
13.

A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).

Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group.

Lung Cancer. 2014 Nov;86(2):195-200. doi: 10.1016/j.lungcan.2014.08.019. Epub 2014 Sep 16.

PMID:
25249428
14.

DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation.

Guha M, Castellanos-Rizaldos E, Makrigiorgos GM.

PLoS One. 2013 Jun 21;8(6):e67782. doi: 10.1371/journal.pone.0067782. Print 2013.

15.

Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.

Wang MC, Wang CL, Chen TL, Chang JW, Lu JJ, Chang PY, Chiou CC.

Clin Chem Lab Med. 2017 Oct 26;55(12):1979-1986. doi: 10.1515/cclm-2016-0809.

PMID:
28787267
16.

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M, Hagiwara K.

Cancer Res. 2005 Aug 15;65(16):7276-82.

17.

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.

Won JK, Keam B, Koh J, Cho HJ, Jeon YK, Kim TM, Lee SH, Lee DS, Kim DW, Chung DH.

Ann Oncol. 2015 Feb;26(2):348-54. doi: 10.1093/annonc/mdu530. Epub 2014 Nov 17.

PMID:
25403583
18.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

19.

The peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations in bronchoscopic cytological specimens of non-small cell lung cancer.

Yamada N, Oizumi S, Asahina H, Shinagawa N, Kikuchi E, Kikuchi J, Sakakibara-Konishi J, Tanaka T, Kobayashi K, Hagiwara K, Nishimura M.

Oncology. 2012;82(6):341-6. doi: 10.1159/000338327. Epub 2012 Jun 2.

PMID:
22677909
20.

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC.

J Clin Oncol. 2012 Feb 1;30(4):433-40. doi: 10.1200/JCO.2011.38.3224. Epub 2012 Jan 3. Erratum in: J Clin Oncol. 2015 Jun 20;33(18):2124.

PMID:
22215752

Supplemental Content

Support Center